RLAY
Relay TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The post-earnings bull case is that May 5 preserved the constructive 2026 setup: cash runway now reaches into 2029, the May vascular-anomalies readout is near, ReDiscover-2 remains active, and management advanced the frontline triplet plan toward an early-2027 Phase 3 start.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +13.3.
What can break
Checked sources did not surface a clear wave of post-earnings analyst target revisions, leaving external validation of the May 5 update limited.
Momentum
91
Value
41
Sentiment
32
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.50 · Bull $17.00 · Bear $8.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $15.80
Why
Momentum91 · Δ7d +13.3
Value41 · Δ7d +0.1
Sentiment32 · Δ7d -2.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
91
34% active weight
Current posture
7d trendImproving
Δ7d
+13.3
Δ21d
-5.7
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
32
33% active weight
Current posture
7d trendSoftening
Δ7d
-2.2
Δ21d
-2.6
Why this grade
Composite grade C. Momentum 90.9 / Value 41.1 / Sentiment 32.1
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$2.69B
Beta
1.60
Shares Out
173.32M
P/E (TTM) · Derived
-9.6
P/S (TTM)
163.03
P/FCF (TTM) · Derived
-10.61
Rev YoY
-23.3%
EPS YoY
+31.5%
Gross Margin
-
Op Margin
-3914.4%
Net Debt
-$781.32M
Current Ratio
19.14
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology